RxDoctor Payments Data

Erin Warren, MD

Internal Medicine · Troy, MINPI 1699122382

Payments from drug & device makers

$2,568in general payments, 2019–2025

Across 142 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$408
  • Boehringer Ingelheim$365
  • AbbVie$248
  • Novo Nordisk$248
  • E.r. Squibb & Sons, L.L.C.$134
  • GSK$134
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,568 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$207,862
Medicare patients
318
Services billed
2,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$175,786
JardianceEmpagliflozin129$172,271
OzempicSemaglutide57$64,325
TrulicityDulaglutide43$62,566
MounjaroTirzepatide40$62,505
JanuviaSitagliptin Phosphate35$44,988
FarxigaDapagliflozin Propanediol29$39,962
XareltoRivaroxaban23$36,672
MyrbetriqMirabegron13$15,948
Breo ElliptaFluticasone/Vilanterol23$11,453
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,223
Atorvastatin Calcium591$8,437
Losartan Potassium372$5,266
Levothyroxine Sodium435$4,922
Pitavastatin Calcium14$4,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$175,786161 claims
Boehringer IngelheimJardiance$365$172,271129 claims
Lilly USA, LLCTrulicity, Mounjaro$408$125,07183 claims
Novo NordiskOzempic$248$64,32557 claims
AstraZenecaFarxiga$104$39,96229 claims
Johnson & JohnsonXarelto$31$36,67223 claims
GSKBreo Ellipta, Trelegy Ellipta$134$22,67634 claims
Astellas Pharma US IncMyrbetriq$72$15,94813 claims
AbbVieSynthroid$248$3,83141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →